Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining...

Descripción completa

Detalles Bibliográficos
Autores principales: Buhl, Anna Sofie Kappel, Christensen, Troels Dreier, Christensen, Ib Jarle, Nelausen, Knud Mejer, Balslev, Eva, Knoop, Ann Søegaard, Brix, Eva Harder, Svensson, Else, Glavicic, Vesna, Luczak, Adam, Langkjer, Sven Tyge, Linnet, Søren, Jakobsen, Erik Hugger, Bogovic, Jurij, Ejlertsen, Bent, Rasmussen, Annie, Hansen, Anker, Knudsen, Steen, Nielsen, Dorte, Jensen, Peter Buhl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208899/
https://www.ncbi.nlm.nih.gov/pubmed/30099635
http://dx.doi.org/10.1007/s10549-018-4918-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208899/
https://www.ncbi.nlm.nih.gov/pubmed/30099635
http://dx.doi.org/10.1007/s10549-018-4918-4

Ejemplares similares